Karyopharm Therapeutics

Karyopharm Therapeutics is a clinical-stage pharmaceutical company. The company is focused on the discovery, development, and commercialization of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The company has discovered and is developing small molecule Selective Inhibitors of Nuclear Export (SINE), compounds that inhibit the nuclear export protein (XPO1). The company's SINE compounds were the first oral XPO1 inhibitors in clinical development. The company is also focusing on commercializing its primary drug candidate, selinexor, as an oral agent in cancer indications with significant unmet clinical need, initially for hematologic malignancies.
  • TickerKPTI
  • ISINUS48576U1060
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Abstract Roundup for Covered Companies

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Abstract Roundup for Covered Companies

A director sold after exercising options/sold 27,042 shares at 9.919USD and

A director at Karyopharm Therapeutics Inc sold after exercising options/sold 27,042 shares at 9.919USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restri...

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

ValuEngine Rating and Forecast Report for KPTI

An unfavourable environment weighs on KARYOPHARM THERP.INCO., which sees a downgrade to Negative

The independent financial analyst theScreener just requalified the general evaluation of KARYOPHARM THERP.INCO. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 2 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date April 16, 2019, the closing price was USD 5.11 and its target price was estimated at USD 3.57.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch